Cover Image

Trastuzumab in esophagogastric cancer: HER2-testing and treatment reality outside clinical studies in Germany

We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated...

Full description

Saved in:
Bibliographic Details
Main Authors: Merx, Kirsten (Author) , Hofheinz, Ralf-Dieter (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Gastroenterology research and practice

ISSN:1687-630X
DOI:undefined
Online Access:Verlag, Volltext: http://dx.doi.org/undefined
Verlag, Volltext: https://www.hindawi.com/journals/grp/2016/1028505/
Get full text
Author Notes:Kirsten Merx, Manuel Barreto Miranda, Lenka Kellermann, Ulrich Mahlknecht, Oliver Lange, Michael Gonnermann, and Ralf-Dieter Hofheinz

MARC

LEADER 00000caa a2200000 c 4500
001 1587618265
003 DE-627
005 20230427034236.0
007 cr uuu---uuuuu
008 190213s2016 xx |||||o 00| ||eng c
035 |a (DE-627)1587618265 
035 |a (DE-576)517618265 
035 |a (DE-599)BSZ517618265 
035 |a (OCoLC)1341038053 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Merx, Kirsten  |d 1970-  |e VerfasserIn  |0 (DE-588)122413091  |0 (DE-627)70589892X  |0 (DE-576)293258910  |4 aut 
245 1 0 |a Trastuzumab in esophagogastric cancer  |b HER2-testing and treatment reality outside clinical studies in Germany  |c Kirsten Merx, Manuel Barreto Miranda, Lenka Kellermann, Ulrich Mahlknecht, Oliver Lange, Michael Gonnermann, and Ralf-Dieter Hofheinz 
264 1 |c 2016 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 13.02.2019 
520 |a We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated outside clinical studies showed a relatively low rate of HER2-testing and insufficient test quality. A total of 2,808 patients retrospectively documented in Therapiemonitor from 2006 to 2013 were analysed regarding treatment intensity and trends in used drugs. Data on HER2-testing and therapies were analysed in two cohorts documented in 2010 and 2011 (1) compared to 2012 and 2013 (2). Treatment intensity increased: 49.3% of patients received at least a triplet in 2013 compared to 10.1% in 2006. In cohort 2 HER2 expression was tested in 79.1% of the cases. Still, in 26.9% testing was not done as requested by guidelines. Good performance status, multiple metastases, age ≤ 65 years, the objective “to prevent progression,“ good cognitive capabilities, estimated good compliance, and social integration positively influenced the probability of HER2-testing; comorbidities negatively affected it. Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2. 
700 1 |a Hofheinz, Ralf-Dieter  |d 1969-  |e VerfasserIn  |0 (DE-588)121917517  |0 (DE-627)08161876X  |0 (DE-576)292991568  |4 aut 
773 0 8 |i Enthalten in  |t Gastroenterology research and practice  |d [Hoboken, NJ : Wiley], 2008  |g (2016) Artikel-Nummer 1028505, 7 Seiten  |h Online-Ressource  |w (DE-627)571608647  |w (DE-600)2435460-0  |w (DE-576)283869534  |x 1687-630X  |7 nnas  |a Trastuzumab in esophagogastric cancer HER2-testing and treatment reality outside clinical studies in Germany 
773 1 8 |g year:2016  |g extent:7  |a Trastuzumab in esophagogastric cancer HER2-testing and treatment reality outside clinical studies in Germany 
856 4 0 |u http://dx.doi.org/undefined  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.hindawi.com/journals/grp/2016/1028505/  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190213 
993 |a Article 
994 |a 2016 
998 |g 121917517  |a Hofheinz, Ralf-Dieter  |m 121917517:Hofheinz, Ralf-Dieter  |d 60000  |d 61200  |e 60000PH121917517  |e 61200PH121917517  |k 0/60000/  |k 1/60000/61200/  |p 7  |y j 
998 |g 122413091  |a Merx, Kirsten  |m 122413091:Merx, Kirsten  |d 60000  |d 61200  |e 60000PM122413091  |e 61200PM122413091  |k 0/60000/  |k 1/60000/61200/  |p 1  |x j 
999 |a KXP-PPN1587618265  |e 3055836227 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Merx, Kirsten","role":"aut","given":"Kirsten","family":"Merx"},{"role":"aut","given":"Ralf-Dieter","display":"Hofheinz, Ralf-Dieter","family":"Hofheinz"}],"name":{"displayForm":["Kirsten Merx, Manuel Barreto Miranda, Lenka Kellermann, Ulrich Mahlknecht, Oliver Lange, Michael Gonnermann, and Ralf-Dieter Hofheinz"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"571608647","origin":[{"dateIssuedKey":"2024","publisher":"Wiley] ; Hindawi","dateIssuedDisp":"2024-","publisherPlace":"[Hoboken, NJ ; New York, NY"}],"note":["Gesehen am 27.07.2021"],"id":{"eki":["571608647"],"zdb":["2435460-0"],"issn":["1687-630X"],"doi":["10.1155/GRP"]},"disp":"Trastuzumab in esophagogastric cancer HER2-testing and treatment reality outside clinical studies in GermanyGastroenterology research and practice","physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2008 -"],"language":["eng"],"part":{"extent":"7","text":"(2016) Artikel-Nummer 1028505, 7 Seiten","year":"2016"},"title":[{"title_sort":"Gastroenterology research and practice","title":"Gastroenterology research and practice"}]}],"note":["Gesehen am 13.02.2019"],"id":{"eki":["1587618265"]},"physDesc":[{"extent":"7 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"2016"}],"recId":"1587618265","language":["eng"],"title":[{"subtitle":"HER2-testing and treatment reality outside clinical studies in Germany","title":"Trastuzumab in esophagogastric cancer","title_sort":"Trastuzumab in esophagogastric cancer"}]} 
SRT |a MERXKIRSTETRASTUZUMA2016 

Similar Items